secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inozyme Pharma, Inc. (—)
CIK:        0001693011
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0000950170-23-027987
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inozyme Pharma amends bylaws for universal proxy rules; shareholders re-elect three directors
--------------------------------------------------------------------------------

- Bylaw amendments enhance disclosure for stockholder nominations and require compliance with SEC Rule 14a-19 universal proxy.
- Stockholders re-elected Martin Edwards, Lynne Sullivan, and Douglas Treco as Class III directors for three-year terms.
- Ratification of Ernst & Young as independent auditor for FY2023 passed with 36,729,818 votes for vs. 10,739 against.
- Other changes include eliminating stockholder list requirement during meetings, remote meeting adjournment for technical failures, and emergency board provisions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/0000950170-23-027987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1693011/000095017023027987/inzy-20230613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer